• Edesa Biotech gets FDA approval for EB05 trial to treat Covid-19 pharmaceutical-technology
    October 22, 2020
    Biopharma firm Edesa Biotech has received clearance from the US Food and Drug Administration (FDA) to initiate the Phase II part of Phase II / III clinical trial of its investigational drug EB05 to treat hospitalised patients with Covid-19.
PharmaSources Customer Service